Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.42 -2.83 (-2.97%)
Delayed Quote Updated: 12:37 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
News headline image
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? ↗
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
Via Chartmill
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Investors buying this biotech stock now will get its pipeline essentially for free. 
Via The Motley Fool
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
From BioNTech SE
Via GlobeNewswire
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Both have attracted considerable attention from Wall Street recently. 
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
From BioNTech SE
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗
BioNTech is preparing for its next phase. 
Via The Motley Fool
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data. 
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
News headline image
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
From BioNTech SE
Via GlobeNewswire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Could it become as successful in this niche as it was in the coronavirus vaccine market? 
Via The Motley Fool
News headline image
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Cathie Wood's biotech ETF has largely moved on from the vaccine maker. 
Via The Motley Fool
Topics ETFs
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
They may not remain cheap for too much longer. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.